首页> 外文期刊>RSC Advances >An innovative strategy to obtain extraordinary specificity in immunofluorescent labeling and optical super resolution imaging of microtubules
【24h】

An innovative strategy to obtain extraordinary specificity in immunofluorescent labeling and optical super resolution imaging of microtubules

机译:在微管的免疫荧光标记和光学超分辨率成像中获得非凡特异性的创新策略

获取原文
获取外文期刊封面目录资料

摘要

When performing immunofluorescent labeling of microtubules, Triton X-100 (TX100) is commonly used as the cell membrane permeabilization agent to improve the accessibility of antigens. Usually, before immunofluorescent labeling, cells are fixed first by aldehydes, followed by permeabilization with TX100. Here, we report an innovative immunofluorescent labeling strategy for microtubules with a meaningful alteration, that is, to treat cells with TX100 first and fix with aldehydes later. We proved that this subtle change can greatly improve the specificity of microtubular immunolabeling. However, treating cells first with TX100 can also severely disrupt the integrity of microtubules if an excessive amount of TX100 is used. Hence, TX100 is a “double-edged sword” in immunofluorescent labeling of microtubules and elaborative control of its dosage is required. In the experiment, we compared different immunofluorescent labeling protocols using various cell lines and found that treating cells with 0.02% TX100 before fixation is an optimal solution. Confocal laser scanning microscopy (CLSM), atomic force microscopy (AFM) and single molecule localization microscopy (SMLM) are utilized to verify the immunofluorescent labeling results performed via the presented unusual protocol. It is possible that such a modified immunofluorescent labeling protocol of microtubules can be generalized as a universal strategy.
机译:当进行微管的免疫荧光标记时,Triton X-100(TX100)通常用作细胞膜通透剂,以改善抗原的可及性。通常,在免疫荧光标记之前,先用醛固定细胞,然后用TX100进行透化。在这里,我们报告了一种具有有意义变化的微管创新免疫荧光标记策略,即先用TX100处理细胞,然后用醛固定。我们证明了这种细微的变化可以大大提高微管免疫标记的特异性。但是,如果使用过量的TX100,则首先用TX100处理细胞也会严重破坏微管的完整性。因此,TX100在微管的免疫荧光标记中是一把“双刃剑”,需要对其剂量进行详尽的控制。在实验中,我们比较了使用各种细胞系的不同免疫荧光标记方案,发现在固定前用0.02%TX100处理细胞是最佳解决方案。利用共聚焦激光扫描显微镜(CLSM),原子力显微镜(AFM)和单分子定位显微镜(SMLM)来验证通过提出的异常方案进行的免疫荧光标记结果。微管的这种改良的免疫荧光标记方案有可能被普遍化为通用策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号